image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.9868
-2.3 %
$ 58.6 M
Market Cap
-0.84
P/E
1. INTRINSIC VALUE

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.[ Read More ]

The intrinsic value of one LUCD stock under the base case scenario is HIDDEN Compared to the current market price of 0.987 USD, Lucid Diagnostics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LUCD

image
FINANCIALS
2.43 M REVENUE
544.03%
-48.5 M OPERATING INCOME
13.69%
-52.7 M NET INCOME
6.24%
-32.8 M OPERATING CASH FLOW
-10.55%
-221 K INVESTING CASH FLOW
94.62%
29.5 M FINANCING CASH FLOW
1028.30%
1.17 B REVENUE
119981.97%
-11.7 B OPERATING INCOME
-104385.35%
-34 B NET INCOME
-308545.01%
-34.2 B OPERATING CASH FLOW
-298148.62%
-387 M INVESTING CASH FLOW
0.00%
30.2 B FINANCING CASH FLOW
259668.29%
Balance Sheet Decomposition Lucid Diagnostics Inc.
image
Current Assets 22.1 M
Cash & Short-Term Investments 18.9 M
Receivables 45 K
Other Current Assets 3.13 M
Non-Current Assets 5.2 M
Long-Term Investments 0
PP&E 2.64 M
Other Non-Current Assets 2.56 M
Current Liabilities 29.4 M
Accounts Payable 1.15 M
Short-Term Debt 15.1 M
Other Current Liabilities 13.2 M
Non-Current Liabilities 199 K
Long-Term Debt 199 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Lucid Diagnostics Inc.
image
Revenue 2.43 M
Cost Of Revenue 8.48 M
Gross Profit -6.05 M
Operating Expenses 42.4 M
Operating Income -48.5 M
Other Expenses 4.18 M
Net Income -52.7 M
RATIOS
-249.18% GROSS MARGIN
-249.18%
-1996.79% OPERATING MARGIN
-1996.79%
-2169.11% NET MARGIN
-2169.11%
2278.93% ROE
2278.93%
-193.13% ROA
-193.13%
-416.55% ROIC
-416.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lucid Diagnostics Inc.
image
Net Income -52.7 M
Depreciation & Amortization 2.5 M
Capital Expenditures -221 K
Stock-Based Compensation 6.82 M
Change in Working Capital 5.68 M
Others 5.78 B
Free Cash Flow -33 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lucid Diagnostics Inc.
image
Wall Street analysts predict an average 1-year price target for LUCD of $2.67 , with forecasts ranging from a low of $2.5 to a high of $3 .
LUCD Lowest Price Target Wall Street Target
2.5 USD 153.34%
LUCD Average Price Target Wall Street Target
2.67 USD 170.23%
LUCD Highest Price Target Wall Street Target
3 USD 204.01%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Lucid Diagnostics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 25, 2023
Sell 286 USD
Lapidus Stanley
Director
- 200
1.43 USD
1 year ago
Sep 26, 2023
Sell 14.7 K USD
Lapidus Stanley
Director
- 10000
1.474 USD
1 year ago
Sep 26, 2023
Sell 14.3 K USD
Lapidus Stanley
Director
- 10000
1.43 USD
1 year ago
Sep 26, 2023
Sell 14.1 K USD
Lapidus Stanley
Director
- 9747
1.45 USD
1 year ago
Sep 20, 2023
Sell 4.94 K USD
Lapidus Stanley
Director
- 3405
1.45 USD
1 year ago
Sep 20, 2023
Sell 593 USD
Lapidus Stanley
Director
- 412
1.44 USD
1 year ago
Sep 21, 2023
Sell 144 USD
Lapidus Stanley
Director
- 100
1.44 USD
1 year ago
Sep 20, 2023
Sell 4.94 K USD
Lapidus Stanley
Director
- 3405
1.45 USD
1 year ago
Sep 20, 2023
Sell 593 USD
Lapidus Stanley
Director
- 412
1.44 USD
1 year ago
Sep 21, 2023
Sell 144 USD
Lapidus Stanley
Director
- 100
1.44 USD
2 years ago
Sep 20, 2022
Sell 29 K USD
Lapidus Stanley
Director
- 17000
1.7067 USD
2 years ago
Sep 20, 2022
Sell 28.7 K USD
Lapidus Stanley
Director
- 16864
1.7 USD
3 years ago
Oct 18, 2021
Bought 8 M USD
PAVmed Inc.
10 percent owner
+ 571428
14 USD
7. News
Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Matt Riley - Director-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Mark Massaro - BTIG Anthony Vendetti - Maxim Group Mike Matson - Needham Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode. seekingalpha.com - 4 days ago
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13 th at 8:30 AM EST NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three months ended September 30, 2024. Conference Call and Webcast The webcast will take place on Wednesday, November 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. prnewswire.com - 4 days ago
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. prnewswire.com - 1 week ago
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets NEW YORK , Nov. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its commercial team has embarked on an expansion of its direct contracting initiative, focusing on programs designed to drive near-term EsoGuard® Esophageal DNA Test revenue, complementing ongoing efforts in traditional reimbursement. These programs include fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets. prnewswire.com - 1 week ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, October 13, 2024, at 8:30 AM ET. During the call,  Lishan Aklog, M.D. prnewswire.com - 2 weeks ago
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its proprietary method of using methylation of the cyclin-A1 (CCNA1) gene to help detect esophageal precancer and cancer, a key component of its EsoGuard® Esophageal DNA Test . "This patent strengthens the already robust intellectual property portfolio underlying our groundbreaking technologies and will provide strong protection for the CCNA1 methylation assay method which is at the heart of the EsoGuard assay," said Lishan Aklog, M.D. prnewswire.com - 1 month ago
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition. benzinga.com - 1 month ago
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition. benzinga.com - 1 month ago
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2024 Maxim Healthcare Virtual Summit. Event Details: Date: Tuesday, October 15, 2024 Time: 11:30 AM Eastern Time Format: Fireside Chat with Dennis McGrath , Lucid's Chief Financial Officer Venue: Virtual For more information about the 2024 Maxim Healthcare Virtual Summit and to attend Lucid's fireside chat, please visit https://m-vest.com/events/healthcare-10152024. prnewswire.com - 1 month ago
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company and several of its key executives will be participating in the upcoming The MedTech Conference 2024, the world's foremost annual medical technology event, which will be held October 15-17, 2024, in Toronto, Canada. The MedTech Conference is organized by AdvaMed, the world's leading medical technology association. prnewswire.com - 1 month ago
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition. marketbeat.com - 1 month ago
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced that the American Foregut Society's (AFS) 2024 Annual Meeting, being held from September 26-28, 2024 at the Gaylord Rockies Resort & Convention Center in Aurora, CO, will be highlighting its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer to conference participants. prnewswire.com - 1 month ago
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK , Sept. prnewswire.com - 2 months ago
8. Profile Summary

Lucid Diagnostics Inc. LUCD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 58.6 M
Dividend Yield 0.00%
Description Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Contact One Grand Central Place, New York, NY, 10165 https://www.luciddx.com
IPO Date Oct. 14, 2021
Employees 70
Officers Mr. Dennis M. McGrath CPA Chief Financial Officer Dr. Sanford D. Markowitz M.D., Ph.D. Co-Founder, Strategic Advisor & Member of the Medical Advisor Board Dr. Suman M. Verma M.D., Ph.D. Chief Scientific Officer Dr. Brian J. deGuzman M.D. Chief Compliance Officer Mr. Michael Adam Gordon General Counsel & Secretary Dr. Amitabh Chak M.D. Co-Founder, Strategic Advisor & Member of Medical Advisory Board Mr. Shaun M. O'Neill M.B.A. President & Chief Operating Officer Dr. Joseph Willis M.D. Cofounder, Strategic Advisor & Member of Medical Advisory Board Richard D. Yazbeck Chief Technology Officer Dr. Lishan Aklog M.D. Chairman & Chief Executive Officer